APA (7th ed.) Citation

Chan, A., Delaloge, S., Holmes, F., Moy, B., Iwata, H., Harvey, V., . . . Martin, M. (2016). Neratinib after trastuzumab-based adjuvant therapy in patients with HER2-positive breast cancer (ExteNET): A multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Elsevier.

Chicago Style (17th ed.) Citation

Chan, Arlene, et al. Neratinib After Trastuzumab-based Adjuvant Therapy in Patients with HER2-positive Breast Cancer (ExteNET): A Multicentre, Randomised, Double-blind, Placebo-controlled, Phase 3 Trial. Elsevier, 2016.

MLA (9th ed.) Citation

Chan, Arlene, et al. Neratinib After Trastuzumab-based Adjuvant Therapy in Patients with HER2-positive Breast Cancer (ExteNET): A Multicentre, Randomised, Double-blind, Placebo-controlled, Phase 3 Trial. Elsevier, 2016.